t e c h n i c a l r e p o r t s
Cellular immunity has an inherent high level of functional heterogeneity. Capturing the full spectrum of these functions requires analysis of large numbers of effector molecules from single cells. We report a microfluidic platform designed for highly multiplexed (more than ten proteins), reliable, sampleefficient (~1 × 10 4 cells) and quantitative measurements of secreted proteins from single cells. We validated the platform by assessment of multiple inflammatory cytokines from lipopolysaccharide (LPS)-stimulated human macrophages and comparison to standard immunotechnologies. We applied the platform toward the ex vivo quantification of T cell polyfunctional diversity via the simultaneous measurement of a dozen effector molecules secreted from tumor antigen-specific cytotoxic T lymphocytes (CTLs) that were actively responding to tumor and compared against a cohort of healthy donor controls. We observed profound, yet focused, functional heterogeneity in active tumor antigen-specific CTLs, with the major functional phenotypes quantitatively identified. The platform represents a new and informative tool for immune monitoring and clinical assessment.
In response to infection or tissue dysfunction, immune cells develop into highly heterogeneous repertoires with diverse functions [1] [2] [3] [4] [5] [6] [7] [8] . A homeostatic makeup of these functional phenotypes dictates the overarching effect of an immune response 4, 9, 10 . For example, tumor-infiltrating macrophages are activated to be either proinflammatory or regulatory depending on their interactions with other cells within the local microenvironment [11] [12] [13] [14] . Viral infection leads to activated T cells with a large variety of effector functions, as reflected by different cytokine profiles 15, 16 . Thus, a comprehensive characterization of the multifunctional phenotypes of single immune cells could provide both fundamental immunobiological information and clinically relevant data 5, 17 .
Common techniques for single-cell protein assays include enzymelinked immunosorbent spot (Fluorospot) and intracellular cytokine staining (ICS) flow cytometry 6 . For enzyme-linked immunosorbent spot assays, typically one to three secreted proteins are detected at the single-cell level. The approach can be quantitative for detecting cytokine-secreting cells, but it does not quantify amounts of the secreted proteins. ICS flow cytometry has enabled the detection of up to five cytokines from single cells. Measurements of polyfunctionality may provide a better indication of in vivo activity, relative to phenotypic classifications based on cell surface markers 4 . This implies the need for measurements of increasing numbers of functions, via multiplex protein assays, from single cells.
Here we report on the single-cell barcode chip (SCBC) for the highcontent assessment of functional heterogeneity at the single-cell level. The chip is comprised of 1,040 3-nl volume microchambers, each loaded with single cells or small defined numbers of cells. Protein concentrations are measured with immunosandwich assays from a spatially encoded antibody barcode. A full barcode represents a complete panel of protein assays, and duplicate barcodes per microchamber enable measurement statistics at the single-cell level. The SCBC permits on-chip, highly multiplexed detection of subthousand copies of proteins and requires only ~1 × 10 4 cells to perform the assay.
We validated the technique with a human macrophage cell line to demonstrate detection of multiple cytokines from single cells. We then implemented it to assay the polyfunctionality of tumor antigen-specific T cells in the setting of an adoptive cell transfer (ACT) therapy clinical trial for melanoma. We observed focused, yet highly heterogeneous, functional diversity compared to samples from healthy donor controls. The SCBC is a high-throughput, low-cost and portable platform that can be used in a wide range of fundamental and clinical applications.
RESULTS

Design rationale and detection limit of the SCBC
The SCBC system consists of four modules ( Fig. 1) : microchannels that contain cells, control valves that isolate cells into microchambers, inlet and outlet ports for the introduction and depletion of reagents and cells and a barcode-encoded glass substrate for protein detection. The chip itself consists of two polydimethylsiloxane (PDMS) layers and fits onto a microscope slide (Fig. 1a) . The bottom PDMS layer has inlets for the loading of reagents and cells that branch into 80 microchannels of 100 µm × 17 µm cross-sectional size. Thirteen sets of vertical valves on the top PDMS layer divide those microchannels into 1,040-nl-volume microchambers. For a microchamber containing one to ten cells, the cell density is 0.3 × 10 6 -3 × 10 6 cells ml −1 , falling into the normal range for culture conditions and physiological environments 18 .
The barcode array is a pattern of parallel stripes, each coated with a distinctive antibody. The stripe width is 25 µm at a pitch of 50 µm. To achieve high and consistent antibody loading, and to prevent antibody denaturation during microfluidics assembly, we used the DNA-encoded antibody library (DEAL) approach 18 , coupled with microchannel-guided Fig. 1 ).
The chemistry and reproducibility of the DNA barcode patterning process has been previously described [19] [20] [21] . The SCBC barcodes contain 13 stripes, 12 for assaying a dozen different proteins and one as a control and spatial reference. Two sets of barcodes are included per microchamber. Cells are randomly loaded so that each SCBC microchamber contains zero to a few cells, following a Gamma Poisson distribution (goodness-offit test: P > 0.8. Supplementary Fig. 2 ). The numbers of cells in each chamber are counted via imaging (Fig. 1b) .
We determined the dynamic range and detection limit of our design by performing on-chip immunoassays with recombinant proteins (Fig. 1c) . The barcode array initially consists of 13 uniquely designed orthogonal DNA strands labeled in order as A through M (Supplementary Table 1 ). Before loading of recombinant proteins, a cocktail containing all capture antibodies conjugated to different complementary DNA strands (A′-L′) is used to transform, via DNA hybridization, the DNA barcode into an antibody array (Fig. 1c) . As few as 100-1,000 copies (1 × 10 −22 -1 × 10 −21 mol) could be detected (3 s.d.), with a dynamic range of three to four orders of magnitude ( Fig. 1e and Supplementary  Fig. 3) , which is compatible with single-cell secretion measurements 18 . Antibody loading, and thus assay sensitivity, was uniform across the whole chip (coefficient of variation (CV) <10%) (Fig. 1d,e) .
Analysis of cytokine production by LPS-stimulated macrophages
We validated the SCBC by using the THP-1 human monocyte cell line. We differentiated the THP-1 cells into cytokine-producing macrophages using phorbol 12-myristate 13-acetate (PMA). Before loading into the device, we added LPS to activate Toll-like receptor 4 (TLR4) signaling 22, 23 , a process that mimics the innate immune response to Gram-negative bacteria (Supplementary Fig. 4 ). For these experiments, we designed the antibody barcode to measure 12 proteins: tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-2 (IL-2), IL-1α, IL-1β, IL-6, IL-10, IL-12, granulocytemacrophage colony-stimulating factor (GM-CSF), chemokine (C-C motif) ligand-2 (CCL-2), transforming growth factor-β (TGF-β) and prostate-specific antigen (PSA) (Supplementary Table 2 ).
The microchambers contained between 0 and 40 cells so that both single-cell behavior and signals from a population could be measured. Through an automated image processing algorithm, we quantified the fluorescence intensities for each protein from each microchamber. For chambers with cells centered between the two barcodes, measurements from the barcode replicates were consistent (CV < 15%, Fig. 2 ). Uncentered cells contributed to variance between replicates (CV up to 50%); however, the averages of the barcode replicates from chambers Frequency with centered and uncentered cells were indistinguishable (P > 0.2, Supplementary Fig. 5 ). Furthermore, measurements between chips showed good consistency (P > 0.2). The intensities of the individual proteins, averaged over many individual SCBC microchamber measurements, agreed with measurements of those same proteins from cell culture supernatants (Fig. 2a) . Secretome data, when binned according to the numbers of cells per chamber, yielded statistically distinct protein signals (P < 0.05, Fig. 2b and Supplementary Fig. 6 ). However, the reference signal was insensitive to the numbers of cells (P > 0.2, Fig. 2b and Supplementary  Fig. 6 ). Most notably, single-cell protein signals could be clearly detected (P < 0.0001, Fig. 2b and Supplementary Fig. 6 ). There was also clear separation of secreting and nonsecreting cells, as visualized by multiple peaks in flow cytometry histograms (Fig. 2c) .
We gated the fraction of cells detected to secrete a given protein using background signals from empty chambers. We measured the frequencies of cells producing TNF-α, IL-1β, IL-10 and GM-CSF to be similar by both SCBC and by ICS flow cytometry ( Fig. 2c  and Supplementary Fig. 6 ). Furthermore, the measured fraction of cells in each quadrant also showed a good similarity between the two techniques ( Fig. 2c and Supplementary Fig. 6 ). Thus, the SCBC platform can efficiently provide a functional profiling of single immune cells. In general, these macrophages showed strongly coordinated functions 24 .
Analysis of polycytokine production by human CTLs
We next turned toward using the SCBC to functionally profile antigen-specific CTLs, which are the main effector cell type of an adaptive immune response targeting intracellular pathogens 25 . CTLs can show a great diversity of antigen specificities, phenotypic surface proteins and functions, and capturing this diversity is a major challenge. Most data suggest that the ability of CTLs to produce multiple cytokines (polyfunctionality) correlates with protective immune responses in vivo 4, 26, 27 .
We assayed the functional diversity of healthy donor CD8 + T cells (n = 3), melanoma-associated antigen recognized by T cells 1 (MART-1)-specific T cell receptor (TCR)-transgenic cells collected from the peripheral blood of an individual with metastatic melanoma participating in an ACT immunotherapy clinical trial, and ex vivo-expanded tyrosinase-specific T cells. TCR engineering provides a means to generate large quantities of antigen-specific T cells amenable to use for the therapy of cancer 28 . 
The TCR-transgenic cells collected from the peripheral blood had been previously generated in vitro by retroviral vector transduction to insert the two chains of a TCR specific for MART-1 and then expanded ex vivo for 2 d followed by re-infusion into the patient after a lymphodepletion conditioning regimen. The patient then received three vaccinations with dendritic cells pulsed with a MART-1 peptide and a high dose of IL-2 to further activate and expand the cells in vivo. Peripheral blood mononuclear cells (PBMCs) were collected on day 30 after re-infusion by leukapheresis, at a time when multiple metastatic melanoma lesions were responding to this therapy. The tyrosinase-specific T cell culture was generated ex vivo from a tyrosinase-specific cell culture obtained by peptide-human leukocyte antigen A0201 (HLA-A0201) tetramer-based selection followed by nonspecific expansion with CD3-specific antibody and IL-2 to obtain a population of nontransgenic but uniform antigen-specific T cells. We enriched the PBMCs for CD3 marker by negative magnetic bead selection before sorting on DEAL-based CD8-specific antibody-coated or peptide-HLA-A0201 tetramer-coated microarrays 29 . Then we released CD3 + CD8 + or CD3 + tetramer + cells from the microarrays. The released T cells underwent activation either by polyclonal TCR engagement of CD3 and CD28-specific antibody binding or by antigen-specific TCR engagement via tetramer and CD28-specific antibody. Activation and SCBC loading was completed within 5 min. To maximize the on-percentage of single-cell measurement to 25-40%, we loaded ~1 × 10 4 sorted T cells in 5 µl medium into the device. Protein heat maps and plots that compare and contrast these different T cell groups are presented in Figure 3 . We included multiple markers that indicate functions such as cytoxicity (perforin), T cell growth and differentiation (IL-2), apoptosis promotion (TNF-α and IFN-γ), inflammation (IL-1β, IL-6 and TNF-β), anti-inflammation (IL-10) and the stimulation and recruitment of other immune compartments (CCL-2, CCL-3CCL-5 and GM-CSF) 27 (Supplementary Table 3) .
More than 20% (median) of the healthy donor CD3 + CD8 + T cells produced TNF-α, IL-6 and the chemokines CCL-2, CCL-3 and CCL-5. The MART-1-specific TCR-transgenic cells that were inducing an objective tumor response in vivo showed a wide range of positive functions demonstrated by the release of perforin, IL-1β, IL-10, IFN-γ, IL-2 and CCL-5 upon ex vivo antigen re-stimulation with the MART-1-HLA-A0201 tetramer. The functionality of the antigen-specific TCR-transgenic cells derived from the subject with melanoma was higher compared to the healthy donor lymphocytes in terms of both signal intensity and fraction of positive cells (Fig. 3a,b,e) . The frequency of cytokine-producing cells among the subject-derived TCR transgenic cells was consistent with Fluorospot results (Fig. 3d) . Phenotyping results identified by flow cytometry of surface markers of T cell phenotype (Fig. 3c) illustrated that the population of subject-derived TCR-transgenic, MART-1-specific cells was mostly homogeneous; the principal (>90%) population of these cells was CD8 + and had a phenotype consistent with effector CCR7 − CD45RA + T cells at a late differentiation stage (Fig. 3c) 15 . In comparison, the ex vivo-expanded tyrosinase-specific T cells showed decreased production of CCL-3, IL-6 and TNF-α (Fig. 3e) . Consistent with the notion that ex vivo expansion of T cells by IL-2 and CD3-specific antibody results in terminal differentiation of T cells, the tyrosinase-specific T cell clone had elevated release of perforin, IL-1β and IL-2, compared to healthy control samples, upon activation ( Fig. 3e and Supplementary Fig. 7) .
Evaluation of polyfunctionality
We analyzed the multivariate features of these T cell populations by studying the protein-protein correlations for two and three proteins. Pseudo-three-dimensional plots (Fig. 4a-c) of markers representing various functions revealed that certain functions of the MART-1-specific cell population were highly coordinated compared to the healthy donor cells. For example, 70% of IL-6 + cells produced CCL-5, whereas for CTLs from healthy donors the frequency was around 50%. TNF-α and IFN-γ production were anticorrelated in MART-1-specific cells (Fig. 4c) , with >90% of the population expressing at most one of these effector molecules. However, for the small fraction of MART-1-specific TCR-transgenic cells that were TNF-α + IFN-γ + , secretion of IL-2 was often an additional function (75% , Fig. 4) . A full set of proteinprotein correlations is provided in Supplementary Figure 8 .
We defined functional subsets of the various T cells by identifying groups of cells that secreted the same combination of proteins (Fig. 4d,e) . There were at least 45 distinct subpopulations that accounted for 60% of the MART-1-specific TCR-transgenic cells (Fig. 4e and Table 1) . A similar accounting for the healthy donor CD8 + T cells and the tyrosinase-specific T cells yields 4-17 subpopulations (Fig. 4d and Table 1) . Furthermore, for the MART-1-specific TCR-transgenic cells, the major functional subsets averaged more than five active functions, whereas both healthy donor and tyrosinase-specific cells averaged only one or two functions ( Table 1) . This demonstrates the ability of SCBC to visualize and discriminate different levels of functional heterogeneity.
DISCUSSION
The SCBC permits highly multiplexed (more than ten proteins) measurements of effector molecules from single cells by detecting the natural protein secretome from macrophages and T cells upon activation. The multiplex capacity can be further expanded beyond what we explored here. The ability to use small sample size (~1 × 10 4 cells) implies that the SCBC can be integrated with other upstream multiplexed analysis, such as flow cytometry or (as we show here) microarray sorting, to enable a detailed functional study of phenotypically defined sets of cells selected from heterogeneous populations. Analysis of signals from chambers containing different numbers of cells may also provide information relevant to cell-cell interactions.
The MART-1-specific TCR-transgenic CTLs had stronger perforin, IFN-γ and interleukin secretion and more functional heterogeneity compared with the healthy donor CTL controls. This functional status is also indicated by their identity as effector T cells (CD45RA + CCL7 − CD27 − CD28 − CD62L − ) 15, 30, 31 . Previous vaccination studies identified that polyfunctional T cells are better cytokine producers and that the quality of a polyfunctional T cell response is a good predictor of clinical outcome 4, 32 . We found that the MART-1-specific TCR-transgenic CTLs showed favorable features compared against CTLs from healthy donors (for example, polyfunctional subset frequency 62% versus 6-25%; Supplementary Fig. 9 ). These data are consistent with the observation that, at the time the CTLs were collected, there was active inflammation and the tumors were responding to the ACT therapy in this patient. We observed signs of T cell terminal effector differentiation and exhaustion, as indicated by the anticorrelation of TNF-α and IFN-γ secretion, high IL-10 + cell frequency and high PD1 and CD127 expression 15 . However, the quality of the T cell response at a single time point within a vaccination trial may not provide an indicator of long-term vaccination or therapy response 4 . A similar multiparameter SCBC analysis carried out at multiple time points throughout the course of a cancer immunotherapy treatment is currently underway.
We saw a high level of functional heterogeneity within a population defined as relatively homogeneous by surface markers 25, 33 , and that heterogeneity was also focused. For example, 45 out of >4,000 possible functional subsets could account for 60% of all MART-1-specific TCR-transgenic cells. The observed high level of polyfunctionality (up to 12 functions per cell, with an average of more than five functions) exceeds current multiplexing capacity by most existing singlecell secretion assays. Moreover, none of the proteins being profiled were interchangeable with others within the panel (with R 2 < 0.6, Supplementary Fig. 8 ). These findings indicate that a high dimensional analysis is in fact required for comprehensively profiling of T cell effector functions.
The SCBC provides a new platform for analyzing the functional activity of immune cells immediately after short-term ex vivo activation. This technology compares favorably to current cellular immunoassays in terms of sensitivity, multiplexing capacity, quantification, sample size, cost and infrastructure requirements and thus has potential for a thorough, cost-effective characterization of human immune cell responses.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
